Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-03-08
2011-03-08
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S252140, C514S252180, C514S252190, C540S601000, C544S295000
Reexamination Certificate
active
07902184
ABSTRACT:
The present invention relates to compounds of formula I and their pharmaceutically acceptable salts wherein formula I is:wherein X, Y, Z, R1and R2are as defined in the description and claims. The compounds of the present invention act as antagonists and/or inverse agonists at the histamine 3 receptor and are useful for the treatment and/or prevention of diseases such as obesity, metabolic syndrome (syndrome X), and other eating disorders.
REFERENCES:
patent: 4598089 (1986-07-01), Hadvary et al.
patent: 4931463 (1990-06-01), Barbier et al.
patent: 4983746 (1991-01-01), Barbier et al.
patent: 5147876 (1992-09-01), Mizuchi et al.
patent: 5175186 (1992-12-01), Barbier et al.
patent: 5246960 (1993-09-01), Barbier et al.
patent: 5399720 (1995-03-01), Karpf et al.
patent: 6004996 (1999-12-01), Shah et al.
patent: 2003/0105106 (2003-06-01), Chiang et al.
patent: 185 339 (1986-06-01), None
patent: 189 577 (1986-08-01), None
patent: 443 449 (1991-08-01), None
patent: 524 495 (1993-01-01), None
patent: WO 99/21834 (1999-05-01), None
patent: WO 99/34786 (1999-07-01), None
patent: WO 00/09122 (2000-02-01), None
patent: WO 00/09123 (2000-02-01), None
patent: WO 00/58293 (2000-10-01), None
patent: WO 03/066604 (2003-08-01), None
Burks, T.F., Physiology of the Gastrointestinal Tract, Johnson L.R. ed., Raven Press, NY, pp. 211-242 (1994).
Leurs et al., Br J. Pharmacol., 102, pp. 179-185 (1991).
Raithel et al., Int. Arch. Allergy Immunol., 108, pp. 127-133 (1995).
Panula et al., Proc. Natl. Acad. Sci. USA, 81, pp. 2572-2576 (1984).
Inagaki et al., J. Comp. Neurol., 273, pp. 283-300 (1988).
Arrang et al., Nature, 302, pp. 832-837 (1983).
Arrang et al., Neuroscience, 23, pp. 149-157 (1987).
Clapham et al., Br. J. Pharmacol., 107, pp. 919-923 (1992).
Blandina et al. in The Histamine H3 Receptor (Leurs, R.L. and Timmermann, H. eds, pp. 27-40 (1998) Elsevier, Amsterdam, The Netherlands.
Masaki et al., Endocrinol., 144, pp. 2741-2748 (2003).
Hancock et al., European J. of Pharmacol., 487, pp. 183-197 (2004).
Timmermann, H., J. Med. Chem., 33, pp. 4-11 (1990).
Takahashi et al., J. Pharmacol. Exp. Therapeutics, 307, pp. 213-218 (2003).
Cheng et al., Biochem Pharmacol, 22, pp. 3099-3108 (1973).
Nettekoven Matthias Heinrich
Roche Olivier
Hoffmann-La Roche Inc.
Johnston George W.
Rao Deepak
Remy Brian C.
Tramaloni Dennis P.
LandOfFree
Piperazinyl pyrimidine derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Piperazinyl pyrimidine derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Piperazinyl pyrimidine derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2673316